Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GEN3009 in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
NCT04358458Phase 2Terminated
- Sponsor
- Genmab
- Start
- Mar 2020
- Primary completion
- Nov 2022
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 5
01
Overview
A Phase 2 trial of ivicentamab in B-cell non-Hodgkin lymphoma, chronic lymphocytic leukemia (CLL), sponsored by Genmab. Started Mar 2020; status: terminated.
02
Drugs
ivicentamab
03
Conditions
B-cell non-Hodgkin lymphomachronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT04358458.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04358458.